These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2573682)

  • 1. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers.
    Mitchell JB; Russo A; Cook JA; Straus KL; Glatstein E
    Int J Radiat Biol; 1989 Nov; 56(5):827-36. PubMed ID: 2573682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers.
    Kinsella TJ; Mitchell JB; Russo A; Morstyn G; Glatstein E
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1399-406. PubMed ID: 6381432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine.
    Cook JA; Glass J; Lebovics R; Bobo H; Pass H; DeLaney TF; Oldfield EH; Mitchell JB; Glatstein E; Goffman TE
    Cancer Res; 1992 Feb; 52(3):719-25. PubMed ID: 1732059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of locally advanced cancer of the head and neck with 5'-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement.
    Epstein AH; Lebovics RS; Goffman T; Teague D; Fuetsch ES; Glatstein E; Okunieff P; Cook JA
    J Natl Cancer Inst; 1994 Dec; 86(23):1775-80. PubMed ID: 7966416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of non-hypoxic cell sensitizers in radiobiology and radiotherapy.
    Mitchell JB; Russo A; Kinsella TJ; Glatstein E
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1513-8. PubMed ID: 3531118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.
    Lawrence TS; Davis MA; Maybaum J; Mukhopadhyay SK; Stetson PL; Normolle DP; McKeever PE; Ensminger WD
    Cancer Res; 1992 Jul; 52(13):3698-704. PubMed ID: 1617642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo.
    Rodriguez R; Ritter MA; Fowler JF; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 1994 Apr; 29(1):105-13. PubMed ID: 8175417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical rationale for S-phase radiosensitization in human tumors.
    McGinn CJ; Kinsella TJ
    Curr Probl Cancer; 1993; 17(5):273-321. PubMed ID: 8281809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour radiosensitization with the halogenated pyrimidines 5'-bromo- and 5'-iododeoxyuridine.
    Epstein AH; Cook JA; Goffman T; Glatstein E
    BJR Suppl; 1992; 24():209-14. PubMed ID: 1290703
    [No Abstract]   [Full Text] [Related]  

  • 10. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure.
    Lawrence TS; Davis MA; Maybaum J; Stetson PL; Ensminger WD
    Int J Radiat Oncol Biol Phys; 1990 Jun; 18(6):1393-8. PubMed ID: 2370189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells.
    Lawrence TS; Davis MA; Maybaum J; Stetson PL; Ensminger WD
    Radiat Res; 1990 Aug; 123(2):192-8. PubMed ID: 2389005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs.
    Kinsella TJ; Dobson PP; Mitchell JB; Fornace AJ
    Int J Radiat Oncol Biol Phys; 1987 May; 13(5):733-9. PubMed ID: 3570896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation.
    Goffman TE; Dachowski LJ; Bobo H; Oldfield EH; Steinberg SM; Cook J; Mitchell JB; Katz D; Smith R; Glatstein E
    J Clin Oncol; 1992 Feb; 10(2):264-8. PubMed ID: 1310102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
    Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
    Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Halogenated pyrimidines as radiosensitizers for high-LET radiation.
    Atcher RW; Russo A; DeGraff WG; Moore M; Grdina DJ; Mitchell JB
    Radiat Res; 1989 Feb; 117(2):351-5. PubMed ID: 2922478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iododeoxyuridine incorporation and radiosensitization in three human tumor cell lines.
    Uhl V; Phillips TL; Ross GY; Bodell WJ; Rasmussen J
    Int J Radiat Oncol Biol Phys; 1992; 22(3):489-94. PubMed ID: 1735685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of radiotherapy by radiosensitizers and cancer chemotherapy agents. I. Radiosensitizers.
    Coleman CN
    Semin Oncol; 1989 Jun; 16(3):169-75. PubMed ID: 2658080
    [No Abstract]   [Full Text] [Related]  

  • 18. Photon activation therapy.
    Fairchild RG; Bond VP
    Strahlentherapie; 1984 Dec; 160(12):758-63. PubMed ID: 6515666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.
    McGinn CJ; Kunugi KA; Tutsch KD; Feierabend C; Alberti D; Lindstrom MJ; Wilding G; Arzoomanian RZ; Kinsella TJ
    Clin Cancer Res; 1996 Aug; 2(8):1299-305. PubMed ID: 9816300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme.
    Jackson D; Kinsella T; Rowland J; Wright D; Katz D; Main D; Collins J; Kornblith P; Glatstein E
    Am J Clin Oncol; 1987 Oct; 10(5):437-43. PubMed ID: 2821790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.